Toledano-Serrabona, Jorge
Bosch, Begoña M.
Díez-Tercero, Leire
Gil, F. Javier
Camps-Font, Octavi
Valmaseda-Castellón, Eduard
Gay-Escoda, Cosme
Sánchez-Garcés, Mª Ángeles
Funding for this research was provided by:
Spanish Government and the Ministry of Science and Innovation of Spain (RTI2018-098075-B-C21 and RTI2018-098075-B-C22)
Instituto de Salud Carlos III (PI20/01596, PI20/01596, PI20/01596, PI20/01596)
Article History
Received: 23 April 2022
Accepted: 8 September 2022
First Online: 22 September 2022
Competing interests
: Jorge Toledano-Serrabona, Leire Díez-Tercero and Begoña M. Bosch Bosch have received no grants, personal fees or non-financial support. F. Javier Gil reports grants from Ministry of Science and Innovation of Spain, during the conduct of the study. F. Javier Gil personal fees, and non-financial support from Klockner Dental Implants (Barcelona, Spain), outside the submitted work. Octavi Camps-Font reports grants from Instituto de Salud Carlos III during the conduct of the study. Octavi Camps-Font reports grants, personal fees and non-financial support from Avinent (Santpedor, Spain), outside the submitted work. Camps-Font has participated as co-investigator in clinical trials sponsored by Mundipharma (Cambridge, UK) and Menarini Richerche (Florence, Italy). Eduard Valmaseda-Castellón reports grants from Instituto de Salud Carlos III during the conduct of the study. Eduard Valmaseda-Castellón reports personal fees and non-financial support from MozoGrau (Valladolid, Spain). He has received personal fees from BioHorizons Ibérica (Madrid, Spain), Inibsa Dental (Lliça de Vall, Spain) and Dentsply implants Iberia (Barcelona, Spain) outside the submitted work. Valmaseda-Castellón is the Director of the Avinent-University of Barcelona research agreement (Càtedra UB-Avinent). In addition, Valmaseda-Castellón has participated as an investigator in clinical trials sponsored by Mundipharma (Cambridge, UK) and Geistlich (Wolhusen, Switzerland), outside the submitted work. Cosme Gay-Escoda reports grants from Instituto de Salud Carlos III during the conduct of the study. Cosme Gay-Escoda reports grants, personal fees, and non-financial support from Mundipharma (Cambridge, UK) and Menarini Richerche (Florence, Italy), outside the submitted work, outside the submitted work. Mª Ángeles Sánchez-Garcés reports grants from Instituto de Salud Carlos III during the conduct of the study. Mª Ángeles Sánchez-Garcés reports personal fees from Nobel Biocare (Göteborg, Sweden), Zimmer Biomet (Warsaw, USA) and Menarini Richerche (Florence, Italy), outside the submitted work.